Psychiatry and Neurology, Neurology · Washington, DC
NPI
1477703312
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
3800 Reservoir Rd NW
Washington, DC, 20007
Phone (301) 675-0014
Groups this clinician bills Medicare through
Medicare paid, 2024
$204K
16,112 services
Medicare patients, 2024
282
Average age 76
Drug cost, 2024
$3.6M
2,707 prescriptions
Company payments, 2025
$272K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fahd S Amjad was code J0588 (injection, incobotulinumtoxin a, 1 unit), 12,985 times for 33 patients. In total Fahd S Amjad billed 16,112 services in 25 codes, and Medicare paid $204K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 12,985 | 33 | $4.07 | $53K |
| J0587 Injection, rimabotulinumtoxinb, 100 units | Office | 1,203 | 13 | $10.22 | $12K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 327 | 93 | $27.10 | $8,861 |
| 99215 Office E&M - Established | Office | 289 | 194 | $143.53 | $41K |
| 99483 Office/Outpatient Services | Office | 137 | 122 | $221.18 | $30K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 120 | 100 | $13.94 | $1,673 |
| 99214 Office E&M - Established | Office | 88 | 69 | $100.36 | $8,832 |
| 95874 Musculoskeletal | Office | 84 | 36 | $67.78 | $5,694 |
| 64616 Musculoskeletal | Office | 65 | 27 | $173.71 | $11K |
| 99205 Office E&M - New | Office | 51 | 51 | $176.20 | $8,986 |
| 64611 Musculoskeletal | Office | 36 | 18 | $107.45 | $3,868 |
| 11105 Skin Biopsy | Office | 32 | 16 | $53.84 | $1,723 |
| 95983 Electrical Nerve Conductivity | Office | 30 | 14 | $40.10 | $1,203 |
| 99213 Office E&M - Established | Office | 17 | 17 | $70.53 | $1,199 |
| 11104 Skin Biopsy | Office | 16 | 16 | $112.52 | $1,800 |
By year: 2022 $254K for 20,595 services; 2023 $209K for 15,289 services; 2024 $204K for 16,112 services.
Medicare prescription drug claims, 2024
In 2024, the drug Fahd S Amjad prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 362 prescriptions and refills. In total Fahd S Amjad wrote 2,707 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 362 | 898 | 117 | $14K |
| Clonazepam Generic | 272 | 367 | 60 | $2,235 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 213 | 544 | 69 | $6,768 |
| Rytary Carbidopa/Levodopa | 191 | 470 | 54 | $319K |
| Nuplazid Pimavanserin Tartrate | 181 | 263 | 32 | $1.3M |
| Rasagiline Mesylate Generic | 167 | 453 | 53 | $29K |
| Memantine Hcl Generic | 124 | 304 | 45 | $5,898 |
| Rivastigmine Generic | 120 | 256 | 45 | $28K |
| Midodrine Hcl Generic | 100 | 260 | 38 | $10K |
| Donepezil Hcl Generic | 92 | 218 | 31 | $2,383 |
| Nourianz Istradefylline | 91 | 129 | 14 | $244K |
| Ongentys Opicapone | 89 | 189 | 21 | $123K |
| Droxidopa Generic | 82 | 120 | 13 | $378K |
| Gabapentin Generic | 53 | 111 | 14 | $1,151 |
| Duloxetine Hcl Generic | 44 | 106 | 12 | $915 |
Brand drugs: 873 claims; generic drugs: 1,834 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fahd S Amjad $272K ($272K in general payments such as food, travel and fees) from 19 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $176K.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 92 | $176K |
| ACADIA Pharmaceuticals Inc ACAD | 84 | $65K |
| Abbvie Inc. ABBV | 38 | $19K |
| Amneal Pharmaceuticals LLC AMRX | 11 | $6,876 |
| MDD US Operations, LLC | 18 | $4,495 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $311 |
| Neurocrine BioSciences, Inc. NBIX | 6 | $217 |
| Abbott Laboratories ABT | 1 | $206 |
| Merz Pharmaceuticals, LLC | 5 | $172 |
| Supernus Pharmaceuticals, Inc. SUPN | 7 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.